Moderna Stock News

Moderna CEO Stephane Bancel Steven Ferdman | Getty Images Moderna’s board of directors approved a golden parachute for CEO Stephane Bancel worth more than $926 million at the end of last year, up from $9.4 million in 2019 before Covid-19 upended the world order. The value of Bancel’s so-called change-in-control package has varied as a […] Moderna CEO Bancel’s golden parachute soared by hundreds of millions over the pandemic

Queensland researchers are set to partner with biotechnology company Moderna to fast-track the development of vaccines against some of the world''s biggest health threats.

The bulk of Bancel''s golden parachute comes in $922.5 million in stock, based on Moderna''s share price as of Dec. 31, 2021.

Moderna Inc (NASDAQ: MRNA ) has dosed the first participant in the Phase 2 study of its omicron-specific bivalent booster candidate (mRNA-1273.214). The vaccine candidate combines Moderna''s omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273). The extension of an earlier study will evaluate mRNA-1273.214 as a single booster dose … Full story available on Benzinga.com

Moderna Inc. disclosed that Chief Executive Stéphane Bancel''s 2021 salary got a 4.7% bump from the year before, while his total compensation jumped 41%, as he received the value of $3.75 million in stock awards his option awards increased 25% to $11.25 million. The increase in compensation comes as the biotechnology company grew revenue by 2,200% to $18.47 billion in 2021, due primarily to the launch of commercial sales of its COVID-19 vaccine, and as the stock soared 143%. In its 2021 proxy statement filed with the Securities and Exchange Commission, the company said Bancel''s base salary rose to $990,385 from $945,673 in 2020 and $921,217 in 2019, while his total compensation grew to $18.16 million from $12.86 million in 2020 and from $8.95 million in 2019. Bancel''s 2021 total comp included $1.5 million in non-equity incentive compensation and $665,354 in "all other compensation," which included $661,004 in security costs. While Bancel''s total comp has increased significantly during the pandemic, this 2021 total was still well below that of 2018, when it reached $58.61 million, including $55.94 million worth of option awards.

President Joe Biden''s COVID-19 program faced some uncertainty Thursday, after U.S. lawmakers passed a massive new bill that would fund the federal government…

Moderna said the first participants in the study had been given the experimental shot in the phase 2 study of Omicron-specific bivalent booster candidate, which combines the company’s current covid-19 vaccine

After months of poor performance, Moderna, BioNTech, and Novavax surged Wednesday. Bears now "are less negative" on Moderna, says one analyst.

It could open the door to major gains in the long term.

Shares of Moderna Inc. were down 1.9% in premarket trading on Thursday after the company said it began dosing patients in a Phase 2 clinical study assessing its experimental bivalent omicron-specific booster. This booster candidate has two components: an omicron-specific booster, and the COVID-19 vaccine, which is based on the original strain of the virus. "Our goal has been to remain ahead of the virus, and we are committed to generating and sharing data with public health authorities as they prepare for the fall booster season," Moderna CEO Stéphane Bancel said in a news release. The study will enroll 375 adults at 20 sites in the U.S. Moderna is also testing a standalone omicron-specific booster candidate in a separate study. Moderna''s stock has tumbled 43.9% so far this year, while the broader S&P 500 is down 10.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Moderna (MRNA) said the first person was dosed in a phase 2 study of its Omicron-specific bivalent booster candidate (mRNA-1273.214).Moderna expects to enroll ~375 people which will…

The biotech company has set an ambitious goal for 2025.